Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 17 Apr 2019 Status changed from not yet recruiting to recruiting.
- 26 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Mar 2019.
- 31 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Jan 2019.